RxDoctor Payments Data

Kazuto Augustus

Podiatrist · Long Beach, CANPI 1952471922

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.2%), travel and lodging and other — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 32.4% of the total. 2025 is the largest year on record at $3,989, 3.0 times the $1,328 reported in 2019. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,231in general payments, 2019–2025

Across 73 payments — averaging $99.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$2K
  • Olympus America Inc.$2K
  • Stryker$1K
  • Paragon 28, Inc.$907
  • Smith+Nephew$286
  • Integra Lifesciences Corporation$224
  • plus $924 from 9 others
$57,532in research payments, 2019–2025

Across 12 payments — averaging $4794.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axogen$58K

What the payments were for

  • Travel & lodging$2,46334%
  • Food & beverage$3,26845%
  • Other$1,50021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,231 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$135,783
Medicare patients
346
Services billed
5,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$8,755
Gabapentin117$1,454
Diclofenac Sodium150$1,392
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$1,097
Cephalexin16$168
Oxycodone Hcl13$38

Paid to pharmacies, not to this prescriber.

Other podiatrist in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →